SCENESSE® (afamelanotide) for treatment of EPP Under the approved labelling of SCENESSE®, the drug is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). Prescribing SCENESSE® Administering SCENESSE® Efficacy and Safety Data